News Sentiment

IOVA sentiment intelligence

Iovance Biotherapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.23 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-1.9% over one week, +3.7% over four weeks, trend active, and below fair value.

Latest direct headline Positive

Iovance Biotherapeutics (NASDAQ:IOVA) jumps 18%, adding a cash balance to its market value

Market Reaction

Balanced read

66/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -1.9% Price digesting
Trend fit Trend active 3.7% over four weeks
Fair value -28.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 26
Neutral 33
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
TradingView 9
simplywall.st 5
Sahm 3
Insider Monkey 3
Stock Titan 3
Ad Hoc News 3
TechStock² 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 17
Regulatory and legal 9
Analyst action 2
Balance sheet 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 62
TradingKey Direct company coverage

Iovance Biotherapeutics Inc (IOVA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Iovance Biotherapeutics Inc (IOVA) has an earnings forecast score of 7.64, ranking 280 out of 388 in its industry. Analysts have an average price target of $9.00 for IOVA, with a "Buy" rating from 10 analysts. The company's expected revenue for the next quarter is $87.76M, and it

Tone
Positive 66/100
Event
Earnings
Published
18 Jun 2026 23:09
Source
TradingKey
TradingView Direct company coverage

Iovance Biotherapeutics Inc Files For Mixed Shelf

Iovance Biotherapeutics Inc. has filed for a mixed shelf offering, according to a report from Refinitiv. This type of filing allows a company to offer a variety of securities over a period of time without having to register each offering separately. The news was published on Trad

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 22:39
Source
TradingView
Stock Titan Direct company coverage

Iovance Biotherapeutics (IOVA) grants 90,316 deferred stock units to director

Iovance Biotherapeutics (IOVA) director Ryan D. Maynard was granted 90,316 deferred restricted stock units (DRSUs) as compensation under the company's 2018 Equity Incentive Plan. These units, each representing one share of common stock, will vest upon R. Maynard's continued servi

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 21:39
Source
Stock Titan